Toronto, Ontario – December 16, 2014 Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that Brian C. Wilson, PhD has agreed to join the Theralase Medical and Scientific Advisory Board (“MSAB”). Dr. Wilson is a Senior Scientist and Head of the Applied Biophotonics group at Princess Margaret Cancer Centre, University Health Network and Professor in the Department of Medical Biophysics at the University of Toronto. The focus of the research of the Applied Biophotonics group is the development and application of new therapeutic and diagnostic techniques based on the use of lasers and other optical technologies. In this translational research, a wide range of methodologies are used: theoretical and experimental studies of light transport in tissues, development of light sources, development of optical-fiber light delivery devices and optical dosimeters, photobiological studies at the cellular and tissue level, in vivo optical spectroscopy of tissues, development of prototype clinical instruments … Read More

Toronto, Ontario – December 9, 2014 Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTC Pink®) announced today that the University of Toledo has conducted in-vitro Photo Dynamic Compound (“PDC”) experimentation that replicates preclinical results obtained earlier by Princess Margaret Cancer Centre, University Health Network (“UHN”), thus validating the Theralase PDC technology at two world renowned institutions. Theralase strategically partnered with the University of Toledo to confirm its in-vitro preclinical PDC results because of the expertise resident in the urology department led by Steve Selman, MD, FACS, Chair and Professor of Urology and Director of Urological Research, University of Toledo, Toledo, Ohio. Dr. Selman stated that, “I am pleased that we have been given the opportunity to work with Theralase and UHN on the preclinical validation of the Theralase PDC technology. The preclinical results we have obtained mirror the results obtained by UHN and thus provide Theralase the comfort that their … Read More

Toronto, Ontario – December 3, 2014 Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Link®) announced today that Michael A. O’Donnell, MD, Professor of Urology, University of Iowa located in Iowa City, Iowa has agreed to join the Theralase Medical and Scientific Advisory Board (“MSAB”). Dr. O’Donnell’s basic and clinical research has a long history of focusing on bladder immunology and bladder cancer immunotherapy, particularly the anti-cancer mechanisms of bacillus Calmette-Guerin (“BCG”) and its enhancement with combination therapies. Dr. O’Donnell recently headed a national trial of bladder cancer treatment utilizing BCG plus interferon (a natural protein which induces healthy cells to combat disease) comprised of over 1,000 patients and holds several U.S. patents for his work. While BCG has long been a standard treatment for bladder cancer, its toxicity profile can be devastating. Dr. O’Donnell’s studies, both laboratory and clinical, seek to both determine the exact mechanism by which BCG targets … Read More

Toronto, Ontario – December 2, 2014 Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Link®) announced today that Ashish M. Kamat, MD, MBBS, FACS, has agreed to join the Theralase Medical and Scientific Advisory Board (“MSAB”). Dr Kamat is an internationally recognized expert in urologic oncology and an authority in the management of urologic cancers. His expertise is with an emphasis on bladder cancer, organ sparing and minimally invasive techniques. Dr Kamat maintains an active research portfolio in this area with a focus on efforts to develop novel therapies, and identifying predictors of response to therapy (e.g. intravesical immunotherapy), as a first step towards personalized cancer therapeutics. He has initiated, led, and been active in several large studies including multinational trials in bladder cancer; these findings have been published in high impact journals. He is recognized internationally for his efforts and has been invited as a visiting professor to several universities … Read More

Toronto, Ontario – November 28, 2014 Theralase Technologies Inc. (“Theralase”) (TLT: TSXV) (TLTFF: OTC Link®) released its third quarter 2014 financial results today, demonstrating a decrease in revenue for the three month period ended September 30, 2014 of 57% and a decrease in revenue of 15% for the nine month period ended September 30, 2014, while making dramatic progress in both its patented next generation Therapeutic Laser Technology (“TLT”) division and its Photo Dynamic Therapy (“PDT”) anti-cancer division. Total revenue for the nine-month period ended September 30, 2014 decreased 15% from $1,165,215 to $994,473 for the same period in 2013. In Canada, revenue decreased 10% to $621,435 from $690,451, in the US, revenue remained flat to $234,167 from $234,128 and internationally revenue decreased 42% to $138,871 from $240,637. The decrease in revenue is mainly attributable to Theralase launching a new sales team and also prospective customers preferring to wait for … Read More

Toronto, Ontario – November 25, 2014 Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTCBB) announced today that it has released a video of the presentations conducted at the Theralase 2013 Annual General Meeting (“AGM”), held on November 14, 2014. The presentations were conducted by Theralase President and CEO, Roger Dumoulin-White and Dr. Lothar Lilge, Professor in the Department of Medical Biophysics University of Toronto and Senior Scientist, Ontario Cancer Institute, Princess Margaret Cancer Centre, University Health Network (“UHN”). Mr. Dumoulin-White presented the strategic vision for both the Therapeutic Laser Technology (“TLT”) division and the Photo Dynamic Therapy (“PDT”) anti-cancer division, while Dr. Lilge presented on the scientific and preclinical data supporting the recent advances in the PDT division. Both Mr. Dumoulin-White and Dr. Lilge were available to answer questions from the audience at the end of their presentations. Dr. Lothar Lilge PhD, Senior Scientist, Ontario Cancer Institute, Princess Margaret Cancer … Read More

Toronto, Ontario – November 12, 2014 Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTCBB) announced today that in new preclinical research, conducted at Princess Margaret Cancer Centre, University Health Network (“UHN”), that it has further validated its Photo Dynamic Compound’s (“PDCs”) ability to destroy a primary host tumour and even more importantly render the animal immune to a repeated exposure of the same cancer. In research conducted at UHN in March 2012, mice were injected with 350,000 colon cancer cells (mouse cell line CT26.CL25) to produce cancerous tumours that were allowed to grow to approximately five millimeters in size. These tumours were treated with an injection of one of Theralase’s lead PDCs and then illuminated by Near Infrared (“NIR”) light to activate the PDC. The vast majority of tumours were completely destroyed. These mice were closely monitored for 20 months post treatment, until November 2013, where they remained cancer free. … Read More

Toronto, Ontario – October 16, 2014 –Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Link®) announced today that it has presented its latest research on the success of its Photo Dynamic Compounds (“PDCs”) in the destruction of cancer and bacteria. This research was presented at the 10th International Symposium on Photodynamic Therapy and Photodiagnosis in Clinical Practice, taking place in Brixen, Italy from October 14 to 18, 2014. Download the Research Cancer remains one of the top human conditions and effective minimal or non-invasive treatments with low side effects and high success rates are urgently needed. Photo Dynamic Therapy (“PDT”), the combination of a Photo Dynamic Compound (“PDC”) and a specific wavelength of light to produce cytotoxic (cell death) oxygen species, has been shown to be a promising avenue for cancer treatment. Theralase’s first preclinical presentation focused on the efficacy of its three lead PDCs to effectively destroy cancer cells … Read More

Toronto, Ontario – October 7, 2014 –Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Link®) announced today that it has collaborated with Sigma-Aldrich Corporation’s (NASDAQ: SIAL) custom manufacturing services business unit SAFC® Commercial , in the manufacture of the Photo Dynamic Compounds (“PDCs”) being developed by Theralase for the destruction of cancer. Under the terms of the agreement, SAFC will develop the Standard Operating Procedures (“SOPs”) to manufacture initial quantities of each of Theralase’s four lead PDCs. Once Theralase selects the final lead PDC at the end of the fourth quarter 2014, SAFC will manufacture both a 100-gram pre-Good Manufacturing Practice (“pre-GMP”) batch and finally a 500-gram GMP batch of the PDC. This final 500-gram batch is intended to be suitable for final sterilization and packaging into individual patient doses for safety and efficacy evaluation through a Health Canada / FDA Phase I/IIa clinical trial, expected in early 2015. SAFC … Read More

Toronto, Ontario – September 24, 2014 –Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Link®) announced today that it has filed a voluntary Annual Information Form (“AIF”) as part of its corporate strategy to become eligible for the registration of a base shelf prospectus as this term is defined in National Instruments 44-101 Short Form Prospectus Distributions and 44-102 Shelf Distributions. Roger Dumoulin-White, President and CEO of Theralase Inc. stated that, “As Theralase executes on its strategic initiatives of launching its next generation therapeutic laser system, the TLC-2000 in 4Q2014 and approval of an Investigational New Drug (“IND”) application for commencement of a Health Canada / FDA Phase I/IIa clinical trial to prove safety and efficacy in Non Muscle Invasive Bladder Cancer (“NMIBC”) in early 2015, Theralase would like to provide all investors the opportunity to invest in the Company and not be limited to accredited investors.” About Theralase Technologies … Read More